Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis. Prediction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results